Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Journey Medical Corporation (DERM)

7.03
+0.15
+(2.18%)
At close: May 2 at 4:00:01 PM EDT
7.03
0.00
(0.00%)
After hours: May 2 at 4:05:05 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Lindsay Allan Rosenwald Executive Chairman 50k -- 1955
Mr. Claude Maraoui Founder, President, CEO & Director 975.43k -- 1967
Mr. Joseph M. Benesch CFO & Corporate Controller 434.09k -- 1967
Mr. Ramsey Alloush COO, General Counsel & Company Secretary -- -- 1986
Mr. Robert Nevin Chief Commercial Officer -- -- 1969
Jaclyn Jaffe Senior Director of Corporate Operations -- -- --

Journey Medical Corporation

9237 East Via de Ventura Boulevard
Suite 105
Scottsdale, AZ 85258
United States
480 434 6670 https://journeymedicalcorp.com
Sector: 
Healthcare
Full Time Employees: 
41

Description

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Corporate Governance

Journey Medical Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 12, 2025 at 8:01 PM UTC - May 25, 2025 at 8:01 PM UTC

Journey Medical Corporation Earnings Date

Recent Events

April 29, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 18, 2025 at 12:00 AM UTC

PRE 14A: Proxy Statements

April 3, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 27, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

March 26, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 24, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 5, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 22, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

Related Tickers

Waiting for permission
Allow microphone access to enable voice search

Try again.